Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The association between seasonal asthma exacerbations and viral respiratory infections in a pediatric population receiving inhaled corticosteroid therapy with or without long-acting beta-adrenoceptor agonist: A randomized study

Charlene M. Prazma a, James E. Gern b, Steven F. Weinstein c, Barbara A. Prillaman a, David A. Stempel a,∗

a GlaxoSmithKline, Research Triangle Park, NC, USA
b University of Wisconsin–Madison, Madison, WI, USA
c Allergy and Asthma Specialists Medical Group, Huntington Beach, CA, USA

1. Introduction

In primary school-aged children, a frequent presentation of asthma is a sudden deterioration in health status, associated with a viral respiratory tract infection (RTI), resulting in signs of airway obstruction, cough, and wheeze [1]. A fall seasonal peak in asthma exacerbations has been reported in many studies and is widely associated with human rhinovirus (HRV) infections [2–8]. Severe asthma exacerbations, requiring the use of systemic corticosteroids (SCS), are a major cause of disease suffering and morbidity, account
for significant asthma-related healthcare costs in the USA [9–11], and are the main risk factor and predictor for future exacerbations [12–14]. The pediatric asthma population, with a past history of fall exacerbations, is particularly vulnerable to respiratory infection upon return to school. This study set out to identify a pediatric population (4–11 years of age) at least 2 weeks prior to returning to their school, who were considered at risk for seasonal exacerbation based on recent prior history of exacerbation requiring treatment with SCS, emergency room (ER) visits or hospitalization. To investigate the viral etiology of exacerbations as they occurred during the fall season, this study utilized an at-home, symptom-driven, method for collection of mucus samples which were subsequently analyzed for viral content. As exacerbations are rare events, this study was not designed to demonstrate a statistically significant difference in exacerbation rates between treatment groups but rather to explore the relationships between treatment, respiratory symptoms, exacerbations, and viral etiology. Mucus sample collection was triggered by the presence of worsening asthma and/or cold symptoms. Samples were analyzed by real-time polymerase chain reaction (RT-PCR) for the presence and identification of virus. The date of mucus collection, the asthma and/or cold symptom pattern, viral etiology, and date of exacerbation treatment facilitated the investigation of the association between viral presence and asthma exacerbation.

This is the first study in an at-risk pediatric population to prospectively explore viral etiology and association with fall asthma exacerbations through symptom-driven collection of mucus samples. It differs from many previous studies in that nasal mucus samples were collected in real time from children following a report of moderate-to-severe respiratory symptoms, rather than at the time of exacerbation. As the study design allowed for more frequent mucus collection, above and beyond times of exacerbation, this study allowed for the observation of viral infection patterns throughout the fall period. The results presented here demonstrate the feasibility of at-home mucus collection in a randomized, clinical trial setting, and provide evidence that the majority of viral infections in children being treated with control medications for persistent asthma do not cause exacerbations of asthma.

2. Methods

2.1. Subject selection

Boys or girls, 4–11 years old, attending daycare or school, with a clinical diagnosis of asthma that required the use of an inhaled corticosteroid (ICS) as mono- or combination controller medication were eligible for inclusion in this study. Subjects were required to have a morning peak expiratory flow (PEF) of ≥70% of predicted at baseline and a history of ≥1 exacerbation of asthma during the previous respiratory viral season (September 2009–May 2010) that required the use of SCS, or an asthma-related urgent care visit, ER visit, or hospitalization during that period. Exclusion criteria included a history of life-threatening asthma in the previous 12 months, evidence of unstable asthma in the week prior to randomization and worsening asthma in the 4 weeks prior to screening, including use of SCS.

2.2. Study design

This was a 16-week, multicenter, randomized, double-blind, parallel-group study designed to explore the relationship between the number of exacerbations and viral RTIs during the fall viral season (September 2010–mid-December 2010; NCT01192178; GSK study identifier: ADA113872). Enrollment was planned for 316 subjects across 40 sites. Subjects were randomized 1:1 to receive fluticasone propionate/salmeterol (FP/SAL) 100/50 mcg or FP 100 mcg, both delivered twice daily via the DISKUS® device for 16 weeks. Subjects were pre-screened for eligibility and were randomized between August 2nd, 2010 and August 13th, 2010. This ensured study treatment was administered for at least 2 weeks prior to the subjects’ return to school. To allow the inclusion of subjects who may have taken a “summer holiday” from their controller medications, subjects were not required to be compliant with the use of their controller medication at the time of randomization. The type of school attended (e.g. traditional calendar, year-round, etc.) and whether it was in session at the time of randomization was collected. Non-study ICS mono- or combination medication was suspended for the duration of the study. Short-acting β2-agonist medication was replaced with albuterol. Subjects were required to withhold albuterol ≥6 h pre-study visit. A placebo group was not included in this study as the population was not required to be on therapy at the time of study entry.

The study protocol, informed consent, and assent documentation were approved by either the central institutional review board or independent ethics committees at each participating site, and written informed consent was obtained from the parents of all subjects prior to any study-specific procedures. In addition, an age-appropriate assent form was used to inform study participants. The study was carried out in accordance with the Declaration of Helsinki, and in compliance with International Conference on Harmonisation Good Clinical Practice guidelines. Funding for this study was provided by GlaxoSmithKline (ADA113872).

2.3. Randomization and blinding

Subjects were assigned to treatment in accordance with a computer-generated randomization schedule through a telephone call to the Interactive Voice Response System. At subsequent visits, a telephone call was made for treatment pack numbers. Both investigators and subjects were blinded to treatment assignment.

2.4. Assessments

Caregivers of subjects kept a daily electronic diary (eDiary) to record asthma measures including morning PEF, asthma symptoms (using a 6-point scale), nighttime awakenings due to asthma, rescue medication use, missed school due to asthma, and upper respiratory symptoms (i.e. cold symptoms, using a 4-point scale). eDiary responses triggered mucus sample collection throughout the study, as described below. Information regarding allergy status (presence/absence and type) was collected by parent report only. The baseline for each of the diary measures was defined as the mean of the diary scores collected in the 7 days immediately following the Randomization Visit.

2.5. Mucus collection

To assess whether asthma exacerbations were associated with respiratory virus infection, subjects were prompted, on a symptom-driven basis, to collect mucus samples. The subjects’ eDiary alerted the subjects when criteria for at-home nasal mucus sample collection were met. Subjects and parents were trained in the at-home collection and freezer storage of mucus samples using the methodology previously reported [15]. The protocol defined the symptom triggers for mucus collection which included the presence of moderate-to-severe upper respiratory symptoms (i.e. cold symptoms) or the worsening of asthma. Worsening asthma symptom triggers were as follows: asthma
symptom score of $\geq 3$ on any 2 consecutive days, increased rescue medication use from baseline, morning PEF below the determined stability limit on 2 consecutive days, nighttime awakening due to asthma on 2 consecutive nights. The morning PEF stability limit was defined as a 20% decrease from the mean morning PEF, which itself was determined from data collected during the first week in the study. The eDiary alerted the subject to collect a mucus sample only once within any given 7-day period.

The presence of moderate-to-severe upper respiratory cold-like symptoms were also collected in the daily eDiary (0 = not present, 1 = mild, clearly present; 2 = moderately severe, uncomfortable; 3 = severe, interfering with sleep or activity). The onset date of a cold was defined retrospectively by the first day of report of moderate-to-severe upper respiratory symptoms as reported in the eDiary (i.e., score of 2 or 3 respectively). A “cold period” was defined as the cold onset day and the following 6 days. Cold onset days were separated by at least 7 days and cold periods did not overlap.

2.6. Viral analysis

At the end of the study, samples were shipped to the University of Wisconsin for viral analysis. Viral analysis was conducted as previously reported using multiplex RT-PCR [15]. A panel of 19 commonly reported respiratory viruses was assessed (Adenovirus B, C and E, Bocavirus, Coronavirus 229E, NL63 and OC43; Enterovirus; Influenzavirus A and B, Metapneumovirus, Para-influenzavirus 1, 2, 3, 4a, and 4b; Rhinovirus; Respiratory Syncytial Virus [RSV] A and B).

2.7. Efficacy assessments

The primary measure of efficacy was the number of asthma exacerbations that occurred during the 2010 fall viral study period (August 30th, 2010–December 16th, 2010). An exacerbation was defined per the protocol as a deterioration of asthma that required the use of outpatient SCS (tablets, suspensions, or injection) or an urgent care visit, hospitalization, or ER visit. Secondary efficacy measures included assessments of symptom severity and duration, and incidence of exacerbations associated with moderate-to-severe upper respiratory infections.

2.8. Health outcomes

Controller status was assessed using the Childhood Asthma Control Test (C-ACT) during clinical visits at baseline and Weeks 4, 8, 12, and 16. C-ACT is a 7-item validated questionnaire completed by subjects (questions 1–4) and the subject’s parent/legal guardian (questions 5–7) [16]. The investigator calculated the total score and transcribed it into the Clinical Trial Report. Scores of <20 indicate that asthma may not be well controlled.

2.9. Safety

Safety was assessed by adverse event (AE) and serious AE (SAE) monitoring throughout the study and 7 days after the last clinical visit by a follow-up phone call.

2.10. Data analysis and statistical methods

The study was designed to be exploratory; therefore, hypothesis tests were considered to be descriptive rather than inferential. Consequently, no multiplicity adjustments to the results of the hypothesis tests were made. Descriptive statistical analysis used SAS version 9.1 software in a UNIX reporting environment. While there were no formal power or sample size calculations, a sample size of 150 subjects per treatment was chosen to support the nature of asthma exacerbations as infrequently occurring events. The analysis population was the intent-to-treat (ITT) population, which included all subjects randomized to study drug.

Secondary measures of efficacy were summarized by treatment group and included severity of asthma symptoms associated with positive viral sample and exacerbations associated with positive viral sample. Exacerbations associated with positive viral sample were analyzed in the same manner as the primary efficacy measure.

3. Results

3.1. Study subjects

A total of 339 subjects (FP/SAL, n = 171; FP, n = 168) from 39 centers in the United States were randomized and included in the ITT population. Of these, 292 (86%) completed the full 16-week study (FP/SAL, n = 147; FP, n = 145). Patient disposition and the reasons for subject withdrawal are shown in Fig. 1. The mean age of the study population was 7.4 years and mean duration of asthma was 4.6 years. The majority of the study population attended traditional calendar school and had not yet returned back to school at the time of randomization (Table 1).

3.2. Collection of mucus samples and identification of respiratory viruses

In total, 429 cold period events, defined by moderate-to-severe asthma symptoms for 6 days, were reported and 75 subjects reported having at least one cold period event. The most common reason for eDiary alert for mucus sample collection was a decrease in PEF below the stability limit (523 events) and rescue medication use (112 events) (Table 2).

Of the 339 study subjects, 227 (67%) collected at least one mucus sample during the study. A total of 537 mucus samples were collected and analyzed. The number of cold period events, eDiary alerts and mucus samples collected were similar between treatment groups (data not shown). In total, 64% (344) of all mucus samples tested positive for at least one respiratory virus. Of the total number of virus positive samples, 80% (276) were HRV positive (Fig. 2). Additional HRV typing was not conducted. The next most frequently detected viruses were Parainfluenzavirus 2 and Coronavirus (NL63 and OC43). The majority (93%) of the virus-positive samples tested positive for the presence of only 1 virus; 24 samples (7%) tested positive for more than 1 virus (Table 3).

3.3. Exacerbations: virus and non-virus associated

During the study, 41 (12%) subjects experienced at least one exacerbation and a total of 49 exacerbations were reported. Mucus samples were collected within 7 days of the exacerbation (i.e. 5 days prior to exacerbation onset and 2 days post) for 27 exacerbations. Of these samples, 20 (74%) were virus positive and 14 (70%) of these were rhinovirus positive. Therefore, of the 344 virus positive mucus samples collected, only 6% were associated with an asthma exacerbation. There were 22 exacerbations for which no mucus sample was collected within the 7-day period surrounding the exacerbation (Fig. 3).

3.4. Asthma control associated with exacerbation

In total, 75% of subjects had well-controlled asthma at baseline with a C-ACT score of $\geq 20$. When comparing baseline control status of those subjects who had an exacerbation during the study with those who did not, it was noted that 34% of the subjects who had an...
exacerbation reported being not well-controlled (C-ACT = 13 – ≤19) at baseline, compared with 24% of those who did not have an exacerbation during the study. At Week 16, the proportion of patients with well-controlled status (C-ACT = ≥20) increased to 88% (Table 4).

In the period surrounding an exacerbation, FP/SAL compared with FP treatment was associated with reduction in rescue medication use and asthma symptoms (Fig. 4). Morning PEF was similarly variable in both treatment groups in the days surrounding exacerbation. A similar ad-hoc analysis was conducted to examine these parameters associated with virus-associated exacerbations, but results were inconclusive due to the low number of virus-associated exacerbations (data not shown).

### 3.5. Safety assessments

In total, 66% (224) of subjects reported AEs and 7% (24) experienced drug-related AEs. A total of 5 non-fatal SAEs were reported in 3 subjects, one of which was hospitalized due to an asthma exacerbation. Reported SAEs included gastroenteritis and syncope in 1 subject each, and RSV pneumonia, respiratory distress and status asthmaticus in 1 subject. No SAEs were considered treatment related. There were no deaths in either treatment group. A total of 2 subjects experienced AEs considered non-serious leading to study withdrawal (deteriorating asthma [n = 1] and abnormal behavior [n = 1]) and SAEs leading to study withdrawal included RSV pneumonia, respiratory distress, status asthmaticus (all in the same subject). The most common AEs reported included upper RTI (18%), headache (16%), cough (14%), pyrexia (11%), and nasopharyngitis (10%). All AEs had a similar incidence between treatment groups, with the exception of sinusitis, which was more commonly reported with FP/SAL (6%) compared with the FP (2%). The most common drug-related AEs were headache (1%) and Upper RTI (1%).

---

**Table 1**

Demographics and other baseline characteristics (ITT population).

| Total (N = 339) |  |
|----------------|---|
| Mean age, years (SD) | 7.4 (2.09) |
| Sex, male, (%) | 220 (65) |
| Race, % |  |
| Caucasian | 256 (76) |
| African American | 60 (18) |
| Asian | 14 (4) |
| Other | 9 (3) |
| Mean duration of asthma, years (SD) | 4.6 (2.52) |
| Allergy history |  |
| No allergies, n (%) | 135 (40) |
| One or more allergies | 203 (60) |
| Number of subjects reporting exacerbations in the prior year, n (%) |  |
| Requiring hospitalization | 25 (7) |
| Requiring oral corticosteroids | 331 (98) |
| Type of school |  |
| Traditional, not started at randomization | 309 (91) |
| Traditional, started when randomized | 14 (4) |
| Daycare | 11 (3) |
| Year-round, not started at randomization | 1 (<1) |
| Year-round, started when randomized | 4 (1) |

* An exacerbation was defined per the protocol as a deterioration of asthma that required the use of outpatient SCS (tablets, suspensions, or injection) or an urgent care visit, hospitalization, or emergency room visit; ITT, intent-to-treat; SCS, systemic corticosteroid; SD, standard deviation.

**Table 2**

Cold and worsening asthma triggers (ITT population).

| Total (N = 339) |  |
|----------------|---|
| Total number of cold period events | 429 |
| Subjects with ≥1 reported cold period | 75 |
| Subjects with 2 reported cold periods | 61 |
| Subjects with ≥3 or more reported cold periods | 56 |
| Number of asthma triggers |  |
| Asthma Symptoms | 30 |
| PEF below stability limit | 523 |
| Nighttime awakenings | 41 |
| Rescue medication use | 112 |
| Multiple asthma triggers | 46 |

* A “cold period” was defined as the cold onset day (day of report of moderate or severe symptoms) and the following 6 days.

b Number of times eDiary alerted subject to collect mucus sample because of increased asthma symptoms; ITT, intent-to-treat.
The common etiology of exacerbations of asthma in children is viral RTIs [17]. The severity and risk of having a viral associated exacerbation may be influenced by factors including atopic status, previous history of exacerbations, pathogenicity of the infecting virus, exposure to allergens, medications taken and medication adherence [17–21]. Several in vitro studies have suggested synergistic benefits of asthma treatment including ICS combined with a long-acting beta-adrenoceptor agonist against HRV [22,23]. This study set out to prospectively assess the frequency and etiology of exacerbations in school-aged subjects during the fall viral epidemic, on a background of FP and FP/SAL maintenance therapy. This study also addressed and confirmed the feasibility of using at-home collection of mucus samples to detect viral etiology in further studies of viral RTIs in subjects with asthma.

The majority of the study population experienced moderate-to-severe cold symptoms at least once during the fall study period.

Based on the time since randomization, the first reports of moderate-to-severe cold symptoms occurred between the second and third week in September and continued throughout the treatment period with no obvious peaks. Worsening asthma symptoms were reported throughout the treatment period with no obvious peaks in reporting.

Viruses were detected in 64% of the mucus samples collected; this frequency is similar to results found in a recent study [24]. As our study employed symptom-driven mucus collection, the viral detection frequency suggests that causes other than viral infection (e.g. allergens, air pollution, etc.) also contributed to respiratory symptoms. Of the samples with positive virology, rhinovirus was the most common respiratory virus identified. This finding is consistent with other reports from fall studies of asthma [25,26].

The number of exacerbations seen during the fall 2010 study treatment period was low; only 41 of 339 (12%) children experienced an exacerbation requiring treatment with SCS or hospitalization. This is notable considering the study was conducted during the peak viral season (September–early December) and in a population considered to be at higher risk of exacerbation based on their past exacerbation history. The frequency of viral association with exacerbation (74%) is similar to viral-associated exacerbation rates reported in other studies conducted in outpatient settings, emergency departments, and hospitals [8,26,27].

A strength of this study, differentiating it from most previous studies of virus-induced exacerbations is that it was a prospective interventional study in which blinded medication was provided to the participants, and adherence to asthma control therapy was monitored and nasal sampling was symptom-driven. This study design is in contrast to observational, cross-sectional, or cohort studies in which adherence to asthma control medications preceding the exacerbation is presumably low and in which nasal samples were collected at scheduled times [28]. Additional strengths of the study included a design which required the population to enter the study in a 2-week period in early August 2010; this enabled treatment of the entire study population for a minimum of 2 weeks prior to the start of most traditional school calendars. Also, the study employed “just in time” mucus sample collection that was driven by the presence of moderate-to-severe upper respiratory symptoms and/or by the presence of signs of

### Table 3

| Virus type, n (%) | Total (n = 339) |
|------------------|----------------|
| Rhinovirus       | 276 (80)      |
| Parainfluenzavirus 2 | 29 (8)      |
| Coronavirus NL63 | 14 (4)       |
| Coronavirus OC43 | 15 (4)       |
| Other*           | 35 (10)      |
| Viruses per sample n (%) |            |
| Positive for 1 virus | 320 (93)    |
| Positive for 2 viruses | 23 (7)      |
| Positive for 3 viruses | 1 (<1)      |

Samples can contain ≥1 virus.

* Upon presence of either moderate to severe cold symptoms or worsening asthma symptoms.

** Percentage of the total number of virus positive samples.

* Enterovirus, Bocavirus, Adenovirus C, Parainfluenza 4b, Parainfluenza 1, Influenza B; ITT, intent-to-treat.

### Discussion

The most common etiology of exacerbations of asthma in children is viral RTIs [17]. The severity and risk of having a viral associated exacerbation may be influenced by factors including atopic status, previous history of exacerbations, pathogenicity of the infecting virus, exposure to allergens, medications taken and medication adherence [17–21]. Several in vitro studies have suggested synergistic benefits of asthma treatment including ICS combined with a long-acting beta-adrenoceptor agonist against HRV [22,23]. This study set out to prospectively assess the frequency and etiology of exacerbations in school-aged subjects during the fall viral epidemic, on a background of FP and FP/SAL maintenance therapy. This study also addressed and confirmed the feasibility of using at-home collection of mucus samples to detect viral etiology in further studies of viral RTIs in subjects with asthma.

The majority of the study population experienced moderate-to-severe cold symptoms at least once during the fall study period.
One limitation of this study was its inability to detect treatment differences, as a result of its exploratory design and the low number of viral RTI-associated exacerbations observed in the study population. Another limitation was the lack of a placebo arm, which would have enabled an assessment of the effect of asthma maintenance treatment on viral etiology and exacerbation rates. Previous randomized pediatric studies and retrospective cohort analyses of populations with similar exacerbation risk and impairment have demonstrated that approximately 30% of subjects experience an exacerbation during the fall \[24,30\], 2.5-fold higher than the 12% exacerbation rate reported in the current study with FP and FP/SAL maintenance therapy. Further placebo-controlled studies are required to examine the effect of maintenance therapy on exacerbations of asthma.

In conclusion, these study results indicate that the large majority of viral RTIs are not associated with fall exacerbations of asthma in at-risk children who are on controller therapy and demonstrate the feasibility and utility of viral monitoring of exacerbations in a therapeutic trial. These findings suggest that additional factors related to virus (e.g. RV species), environment, and/or host help to determine the risk of virus-induced exacerbations. Understanding the relationships between exacerbations of asthma and viral RTIs may provide new insights to improve therapeutic strategies aimed at managing asthma exacerbations.

**Disclosures**

C.M. Prazma and D.A. Stempel are employees of GlaxoSmithKline, own stocks/shares in GlaxoSmithKline, and were involved in the study design, data collection and analysis. B.A. Prillaman was an employee of GlaxoSmithKline and holds stocks of GlaxoSmithKline and now is an employee of PAREXEL and was involved in the study design, data collection and analysis. J.E. Gern is a paid employee of the University of Wisconsin and was involved in the study design by advising on mucus sample data collection, process and technique. The viral data analysis was conducted at the University of Wisconsin and was involved in the study design, data collection and analysis. J.E. Gern is a paid employee of Indicia Ltd was funded by GSK.

**Fig. 4.** Summary of the mean change in daily asthma symptoms and rescue medication use (ITT population): A) Change from day –7 to 7 in mean daily asthma symptom score and 7 days prior and 7 days following exacerbation. B) Change from day –7 to 7 in mean daily rescue medication use in the 7 days prior and 7 days following exacerbation. Mean values were determined for subjects in each treatment group on each day for a 2-week period surrounding the exacerbation. The first day of exacerbation treatment with ICS was determined as Day 0. FP, fluticasone propionate; FP/SAL, fluticasone propionate/salmeterol; ITT, intent-to-treat.

Table 4

| Asthma control status \(^{a}\) (ITT population) | Total |
|-----------------------------------------------|-------|
| Baseline – ITT \(^{a}\) N = 339                |       |
| Total Score, n (%)                            |       |
| ≥20                                           | 254 (75) |
| 13 to <19                                     | 85 (25)  |
| <12                                          | 0      |
| Baseline – Exacerbators                       | n = 41 |
| Total score, n (%)                            |       |
| ≥20                                           | 27 (66)  |
| 13 to <19                                     | 14 (34)  |
| <12                                          | 0      |
| Baseline – Non-exacerbators                   | n = 298|
| Total score, n (%)                            |       |
| ≥20                                           | 227 (76) |
| 13 to <19                                     | 71 (24)  |
| <12                                          | 0      |
| Week 16 – ITT                                 | n = 292|
| Total score, n (%)                            |       |
| ≥20                                           | 256 (88) |
| 13 to <19                                     | 33 (11)  |
| <12                                          | 3 (1)   |

\(^{a}\) C-ACT ≥20 – well controlled status; 13 to <19 – not well controlled status; <12 – poorly controlled status; C-ACT, Childhood Asthma Control Test; ITT, intent-to-treat.
References

[1] L.B. Bacharier, B.R. Phillips, G.R. Bloomberg, R.S. Zeiger, I.M. Paul, M. Krawiec, et al., Severe intermittent wheezing in preschool children: a distinct phenotype, J. Allergy Clin. Immunol. 119 (2007) 604–610.

[2] K.B. Weiss, Seasonal trends in US asthma hospitalizations and mortality, JAMA 263 (1990) 2323–2328.

[3] R.E. Dales, I. Schweitzer, J.H. Toogood, M. Drouin, W. Yang, J. Dolovich, et al., Respiratory infections and the autumn increase in asthma morbidity, Eur. Respir. J. 9 (1996) 72–77.

[4] Y. Mao, R. Semenciw, H. Morrison, D.T. Wigle, Seasonality in epidemics of asthma mortality and hospital admission rates, Ontario, 1975-86, Can. J. Public Health 81 (1990) 226–228.

[5] D. Kimes, E. Levine, S. Timmins, S.R. Weiss, M.E. Bollinger, C. Blaisdell, Temporal dynamics of emergency department and hospital admissions of pediatric asthmatics, Environ. Res. 94 (2004) 7–17.

[6] D. Lincoln, G. Morgan, V. Sheppeard, B. Jalaludin, T.E. Pappas, L.E. Salazar, et al., Weekly asthma and return to school in Sydney, Australia, Public Health 120 (2006) 854–862.

[7] W.D. Rawlinson, Z. Waliuzzaman, I.W. Carter, Y.C. Belessis, K.M. Gilbert, S.L. Johnston, P.K. Pattemore, G. Sanderson, S. Smith, F. Lampe, L. Josephs, et al., Community study of role of viral infections in exacerbations of asthma in 9–11 year old children, BMJ 310 (1995) 1225–1229.

[8] J.E. Moorman, R.A. Rudd, C.A. Johnson, M. King, P. Minor, C. Bailey, et al., National surveillance for asthma—United States, 1980–2004, MMWR Surveill. Summ. 56 (2007) 1–54.

[9] L.J. Akinbami, J.E. Moorman, X. Liu, Asthma Prevalence, Health Care Use, and Mortality: United States, 2005–2009, Natl Health Stat Report, 2011, pp. 1–14.

[10] J.A. Dilley, R.A. Praznac, S.C. Macdonald, J. Bardin, Childhood asthma and return to school in Sydney, Australia, Public Health 120 (2006) 834–840.

[11] W.W. Busse, W.J. Morgan, P.J. Gergen, H.E. Mitchell, J.E. Gern, A.H. Liu, et al., Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children, N. Engl. J. Med. 364 (2011) 1005–1015.

[12] L.C. Denlinger, R.L. Sorkness, W.M. Lee, M.D. Evans, M.J. Wollf, S.K. Mathur, et al., Lower airway rhinovirus burden and the seasonal risk of asthma exacerbation, Am. J. Respir. Crit. Care Med. 184 (2011) 1007–1014.

[13] C.M. Prazma, K.M. Kral, N. Gul, S.W. Yancey, D.A. Stempel, Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections, Respir. Med. 104 (2010) 780–787.

[14] H.K. Reddel, D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, W.W. Busse, et al., Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus, Clin. Exp. Allergy 39 (2009) 1700–1710.

[15] W.W. Busse, W.J. Morgan, P.J. Gergen, H.E. Mitchell, J.E. Gern, A.H. Liu, et al., Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial, Lancet 377 (2011) 1318–1324.

[16] C.M. Prazma et al. / Respiratory Medicine 109 (2015) 1280–1286